Advertisement Pharmaceutical Business review - Page 3221 of 5286 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 18, 2026

Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status

Faeth Therapeutics has received the US Food and Drug Administration’s (FDA) fast track designation for the sapanisertib and serabelisib (PIKTOR) with paclitaxel combination to treat advanced or recurrent endometrial cancer.

Faeth Therapeutics is conducting a Phase II trial, Study FTH-PIK-201, in second-line advanced endometrial cancer. Credit: Jo Panuwat D / Shutterstock.com.